Prestige Consumer Healthcare (PBH) Non-Current Debt (2011 - 2026)
Prestige Consumer Healthcare (PBH) posted quarterly Non-Current Debt of $1.0 billion for Q4 2025, up 4.19% year-over-year from $992.0 million in Q4 2024, and up 4.07% quarter-over-quarter from $993.1 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Non-Current Debt (2011 - 2026) Analysis & Trends
Prestige Consumer Healthcare's Non-Current Debt history runs 15 years deep, the most recent figure standing at $1.0 billion for Q4 2025.
- In Q4 2025, Non-Current Debt rose 4.19% year-over-year to $1.0 billion; the TTM figure through Dec 2025 stood at $1.0 billion (up 4.19% YoY), while the FY2025 annual figure was $992.4 million, down 11.85% from the prior year.
- Non-Current Debt for Q4 2025 stood at $1.0 billion, up from $993.1 million in the prior quarter.
- The five-year high for Non-Current Debt was $1.6 billion in Q3 2021, with the low at $992.0 million in Q4 2024.
- The 5-year median for Non-Current Debt is $1.3 billion (2023), against an average of $1.3 billion.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt decreased 17.29% in 2024, then advanced 4.19% in 2025.
- Prestige Consumer Healthcare's Non-Current Debt stood at $1.5 billion in 2021, then decreased by 6.94% to $1.4 billion in 2022, then fell by 15.78% to $1.2 billion in 2023, then fell by 17.29% to $992.0 million in 2024, then grew by 4.19% to $1.0 billion in 2025.
- Business Quant data shows PBH's Non-Current Debt at $1.0 billion in Q4 2025, $993.1 million in Q3 2025, and $992.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 130.00 Mn |
| 10 | Prestige Consumer Healthcare | 2.44 Bn | 2.37 Bn | - | 993.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 993.95 Mn |
| Dec 31, 2025 | 1.03 Bn |
| Sep 30, 2025 | 993.15 Mn |
| Jun 30, 2025 | 992.75 Mn |
| Mar 31, 2025 | 992.36 Mn |
| Dec 31, 2024 | 991.97 Mn |
| Sep 30, 2024 | 1.05 Bn |
| Jun 30, 2024 | 1.09 Bn |
| Mar 31, 2024 | 1.13 Bn |
| Dec 31, 2023 | 1.20 Bn |
| Sep 30, 2023 | 1.26 Bn |
| Jun 30, 2023 | 1.32 Bn |
| Mar 31, 2023 | 1.35 Bn |
| Dec 31, 2022 | 1.42 Bn |
| Sep 30, 2022 | 1.44 Bn |
| Jun 30, 2022 | 1.47 Bn |
| Mar 31, 2022 | 1.48 Bn |
| Dec 31, 2021 | 1.53 Bn |
| Sep 30, 2021 | 1.59 Bn |
| Jun 30, 2021 | 1.55 Bn |